Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Open-label Study of Dupilumab in Patients With Atopic Dermatitis

ClinicalTrials.gov ID: NCT01949311

Public ClinicalTrials.gov record NCT01949311. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 1, 2026, 11:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-label Study of Dupilumab in Patients With Atopic Dermatitis Who Participated in Previous Dupilumab Clinical Trials

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objective is to assess the long-term safety of dupilumab administered in adult participants with atopic dermatitis (AD). The secondary objective of the study is to assess the immunogenicity of dupilumab in adult participants with AD, in the context of re-treatment, and to monitor efficacy parameters associated with long-term treatment. Optional Sub-Study: The primary objective of the sub-study is to assess the safety of the new dupilumab drug product in adult patients with AD after switching from the current dupilumab drug product. The secondary objectives of the sub-study are to evaluate systemic exposure and immunogenicity of the new dupilumab drug product in adult patients with AD.

Study identification

NCT ID
NCT01949311
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Regeneron Pharmaceuticals
Industry
Enrollment
2,733 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 9, 2013
Primary completion
Jun 26, 2022
Completion
Jun 26, 2022
Last update posted
Oct 16, 2023

2013 – 2022

United States locations

U.S. sites
129
U.S. states
35
U.S. cities
103
Facility City State ZIP Site status
Regeneron Study Site Anniston Alabama 36207
Regeneron Study Site Birmingham Alabama 35205
Regeneron Study Site 1 Birmingham Alabama 35209
Regeneron Study Site 2 Birmingham Alabama 35233
Regeneron Study Site 2 Phoenix Arizona 85018
Regeneron Study Site 3 Phoenix Arizona 85023
Regeneron Study Site 1 Phoenix Arizona 85032
Regeneron Study Site Fort Smith Arkansas 72916
Regeneron Study Site Rogers Arkansas 72758
Regeneron Study Site Bakersfield California 93309
Regeneron Study Site Clovis California 93612
Regeneron Study Site Costa Mesa California 92626
Regeneron Study Site Encinitas California 92024
Regeneron Study Site Fremont California 94538
Regeneron Study Site Lomita California 90717
Regeneron Study Site Long Beach California 90808
Regeneron Study Site 1 Los Angeles California 90025
Regeneron Study Site 2 Los Angeles California 90025
Regeneron Study Site Los Angeles California 90045
Regeneron Study Site Oceanside California 92056
Regeneron Study Site Orange California 92868
Regeneron Study Site Rolling Hills Estates California 90274
Regeneron Study Site San Diego California 92122
Regeneron Study Site 1 San Diego California 92123
Regeneron Study Site 2 San Diego California 92123
Regeneron Study Site Santa Monica California 90404
Regeneron Study Site Centennial Colorado 80112
Regeneron Study Site Denver Colorado 80206
Regeneron Study Site Denver Colorado 80220
Regeneron Study Site Trumbull Connecticut 06611
Regeneron Study Site Washington D.C. District of Columbia 20037
Regeneron Study Site Boca Raton Florida 33486
Regeneron Study Site Clearwater Florida 33756
Regeneron Study Site Fort Lauderdale Florida 33306
Regeneron Study Site 1 Jacksonville Florida 32216
Regeneron Study Site 2 Jacksonville Florida 32216
Regeneron Study Site Lake Worth Florida 33461
Regeneron Study Site Miami Florida 33135
Regeneron Study Site Miami Florida 33144
Regeneron Study Site Miami Lakes Florida 33016
Regeneron Study Site Orlando Florida 32806
Regeneron Study Site Tampa Florida 33607
Regeneron Study Site Tampa Florida 33614
Regeneron Study Site Tampa Florida 33624
Regeneron Study Site West Palm Beach Florida 33406
Regeneron Study Site Alpharetta Georgia 30022
Regeneron Study Site Atlanta Georgia 30322
Regeneron Study Site Columbus Georgia 31904
Regeneron Study Site Macon Georgia 31217
Regeneron Study Site Newnan Georgia 30263
Regeneron Study Site Sandy Springs Georgia 30328
Regeneron Study Site Savannah Georgia 31405
Regeneron Study Site Chicago Illinois 60611
Regeneron Study Site Normal Illinois 61761
Regeneron Study Site West Dundee Illinois 60118
Regeneron Study Site Indianapolis Indiana 46250
Regeneron Study Site Newburgh Indiana 47630
Regeneron Study Site Plainfield Indiana 46168
Regeneron Study Site Overland Park Kansas 66215
Regeneron Study Site New Orleans Louisiana 70112
Regeneron Study Site Rockville Maryland 20850
Regeneron Study Site Boston Massachusetts 02111
Regeneron Study Site Boston Massachusetts 02114
Regeneron Study Site Boston Massachusetts 02115
Regeneron Study Site Bay City Michigan 48706
Regeneron Study Site Farmington Hills Michigan 48334
Regeneron Study Site Troy Michigan 48084
Regeneron Study Site Edina Minnesota 55435
Regeneron Study Site Fridley Minnesota 55432
Regeneron Study Site Minneapolis Minnesota 55402
Regeneron Study Site Plymouth Minnesota 55402
Regeneron Study Site Saint Joseph Missouri 64506
Regeneron Study Site St Louis Missouri 63104
Regeneron Study Site St Louis Missouri 63141
Regeneron Study Site Henderson Nevada 89052
Regeneron Study Site Las Vegas Nevada 89119
Regeneron Study Site Portsmouth New Hampshire 03801
Regeneron Study Site Berlin New Jersey 08009
Regeneron Study Site East Windsor New Jersey 08520
Regeneron Study Site Verona New Jersey 07044-2946
Regeneron Study Site 1 Albuquerque New Mexico 87106
Regeneron Study Site 2 Albuquerque New Mexico 87106
Regeneron Study Site Buffalo New York 14203
Regeneron Study Site Corning New York 14830
Regeneron Study Site Forest Hills New York 11375
Regeneron Study Site New York New York 10016
Regeneron Study Site New York New York 10021
Regeneron Study Site New York New York 10029-6501
Regeneron Study Site New York New York 10075
Regeneron Study Site Rochester New York 14642
Regeneron Study Site Chapel Hill North Carolina 27516
Regeneron Study Site High Point North Carolina 27262
Regeneron Study Site Raleigh North Carolina 27612
Regeneron Study Site Wilmington North Carolina 28405
Regeneron Study Site Winston-Salem North Carolina 27104
Regeneron Study Site Cincinnati Ohio 45231
Regeneron Study Site Cleveland Ohio 44106
Regeneron Study Site Norman Oklahoma 73071
Regeneron Study Site Tulsa Oklahoma 74136
Regeneron Study Site Medford Oregon 97504-9741
Regeneron Study Site Portland Oregon 97223
Regeneron Study Site Portland Oregon 97239
Regeneron Study Site Bethlehem Pennsylvania 18020
Regeneron Study Site Jenkintown Pennsylvania 19046
Regeneron Study Site Philadelphia Pennsylvania 19104
Regeneron Study Site Pittsburgh Pennsylvania 15213
Regeneron Study Site Charleston South Carolina 29407
Regeneron Study Site Greer South Carolina 29650
Regeneron Study Site Chattanooga Tennessee 37421
Regeneron Study Site Nashville Tennessee 37215
Regeneron Study Site Arlington Texas 76011
Regeneron Study Site Austin Texas 78705
Regeneron Study Site Bellaire Texas 77401-3505
Regeneron Study Site Dallas Texas 75230
Regeneron Study Site Dallas Texas 75231
Regeneron Study Site Dallas Texas 75246
Regeneron Study Site Houston Texas 77004
Regeneron Study Site San Antonio Texas 78218
Regeneron Study Site 1 San Antonio Texas 78229
Regeneron Study Site 2 San Antonio Texas 78229
Regeneron Study Site San Antonio Texas 78258
Regeneron Study Site Waco Texas 76710
Regeneron Study Site Webster Texas 77598
Regeneron Study Site Salt Lake City Utah 84132
Regeneron Study Site South Burlington Vermont 05403
Regeneron Study Site Newport News Virginia 23606-4537
Regeneron Study Site Norfolk Virginia 23502
Regeneron Study Site Richmond Virginia 23220
Regeneron Study Site Seattle Washington 98101

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 303 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01949311, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 16, 2023 · Synced Sep 1, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01949311 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →